Compare PDYN & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDYN | VCRE |
|---|---|---|
| Founded | 1983 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.2M | 271.7M |
| IPO Year | 2020 | 2026 |
| Metric | PDYN | VCRE |
|---|---|---|
| Price | $4.10 | $9.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $10.75 | ★ $29.03 |
| AVG Volume (30 Days) | ★ 833.1K | 24.1K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,246,000.00 | N/A |
| Revenue This Year | $373.67 | $101.29 |
| Revenue Next Year | $61.05 | $481.15 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.14 | $7.88 |
| 52 Week High | $10.00 | $14.01 |
| Indicator | PDYN | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 20.61 | 41.99 |
| Support Level | N/A | $8.34 |
| Resistance Level | $6.95 | $12.08 |
| Average True Range (ATR) | 0.23 | 0.88 |
| MACD | -0.11 | 0.02 |
| Stochastic Oscillator | 11.64 | 29.61 |
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.